Merck to buy Prometheus Bio.......for an all cash deal worth $10.8b usd. Prometheus is currently trading at $115usd, so I guess shareholders can expect to receive $230usd per share, considering the 47.3 million outstanding shares. Similar math would see Oncy receive a buyout offer of $2.30usd per share, considering their current SP. What a sincerely pathetic situation we shareholders find ourselves in. Great job BOD!!!